Translate page

CML publications 2021

Clinical Publications Scientific Publications
December 2021
Emerging concepts for assessing and predicting treatment-free remission in chronic myeloid leukemia patients
Breccia M et al. Expert Rev Hematol,
December 2021 (epub ahead of print)
Shedding light on targeting chronic myeloid leukemia stem cells
Houshmand M et al. J Clin Med, December 2021
– open access publication 
Low-dose dasatinib in older patients with chronic myeloid leukemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trial
Murai K et al. Lancet Haematol, December 2021
Antimetabolic cooperativity with the clinically approved L-asparaginase and tyrosine kinase inhibitors to eradicate CML stem cells
Trinh A et al. Mol Metab, December 2021
– open access publication 
Low-dose dasatinib: when less can be more
Amrein PC. Lancet Haematol, December 2021
Description of PTPRG genetic variants identified in a cohort of chronic myeloid leukemia patients and their ability to influence response to tyrosine kinase inhibitors
Ismail MA et al. Gene, December 2021 (epub ahead of print) – open access publication 
Blast and accelerated phase CML: room for improvement
How J et al. Hematology Am Soc Educ Program, December 2021 – open access publication
Quantitative proteomic analysis of plasma exosomes to identify the candidate biomarker of imatinib resistance in chronic myeloid leukemia patients
Li MY et al. Front Oncol, December 2021
– open access publication 
Matchpoint: the game is not over for blast-phase chronic myeloid leukemia
Rousselot P. Lancet Hematol, December 2021
(epub ahead of print)
Large-scale topological disruption of chromosome territories 9 and 22 is associated with nonresponse to treatment in CML
Fabian-Morales E et al. Int J Cancer, December 2021
(epub ahead of print) – open access publication 
Chronic myeloid leukemia, BCR-ABL1-positive, carrying NPM1 mutation – First case series from a single institution
Young PE et al. Leuk Res, December 2021
Screening and identification of key genes in imatinib-resistant chronic myelogenous leukemia cells: a bioinformatics study
Zhang H et al. Hematology, December 2021
– open access publication 
TKI discontinuation in CML: how do we make more patients eligible? How do we increase the chances of a successful treatment-free remission?
Hochhaus A and Ernst T. Hematology Am Soc Hematol Educ Program, December 2021
- open access publication
Neutrophil extracellular traps are increased in chronic myeloid leukemia and are differently affected by tyrosine kinase inhibitors
Telerman A et al. Cancers(Basel), December 2021
– open access publication
Lifelong TKI therapy: how to manage cardiovascular and other risks
Mauro MJ. Hematology Am Soc Hematol Educ Program, December 2021 – open access publication
A bis-pyridinium fullerene derivative induces the generation of ROS in BCR-ABL-positive leukemia cells
Sumi K et al. Eur J Pharmacol, December 2021 (epub ahead of print)
Ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-crisis chronic myeloid leukemia (MATCHPOINT): a single-arm, multicentre phase 1/2 trial
Copland M et al. Lancet Haematology,
December 2021 (epub ahead of print)
Simvastatin potentiates the cell-killing activity of imatinib in imatinib-resistant chronic myeloid leukemia cells mainly through PI3K/AKT pathway attenuation and Myc downregulation
Ding L et al. Eur J Pharmacol, December 2021 
Efficacy and safety following bosutinib dose reduction in patients with Philadelphia chromosome-positive leukemias
Kota V et al. Leuk Res, December 2021
SOCS-2 gene expression at diagnosis does not predict for outcome of chronic myeloid leukemia patients on imatinib treatment
Egeli DB et al. Leuk Lymphoma, December 2021 (epub ahead of print)
Chronic myeloid leukemia stem cells targeting therapeutic implications
Mojtahedi H et al. Stem Cell Res Ther, December 2021
– open access publication
The effect of Gö6976 on chronic myeloid leukemia in vitro and in vivo
Cao ZR et al. Hematology, December 2021
BCR-ABL1 p210 screening for chronic myeloid leukemia in patients with peripheral blood cytoses
Fenu E et al. Int J Lab Hematol, December 2021
Potential approaches versus approved or developing chronic myeloid leukemia therapy
Andretta E et al. Front Oncol, December 2021
– open access publication
Clinical outcome of chronic myeloid leukemia patients who switch from first-line therapy with a second-generation tyrosine kinase inhibitor to an alternative TKI
Ma CE et al. Leuk Res, December 2021
 
Overview of clinical and genetic features of CML patients with variant Philadelphia translocations involving chromosome 7: A case series
Bayrak AG et al. Leuk Res, December 2021

 

 

Second-generation tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia patients with stable deep molecular response: A systematic review and meta-analysis
Di Q et al. Comput Math Methods Med, December 2021 – open access publication 

 
November 2021
Droplet digital PCR for BCR-ABL1 monitoring in diagnostic routine: Ready to start?
Bochiccio MT et al. Cancers (Basel), Oct 2021
– open access publication
Tnfrsf4-expressing regulatory T cells promote escape of chronic myeloid leukemia stem cells
Hinterbrandner M et al. JCI Insight, November 2021
(epub ahead of print)
– open access publication 
A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs
Réa D et al. Blood, November 2021
Global identification of circular RNAs in imatinib (IM) resistance of chronic myeloid leukemia (CML) by modulating signaling pathways of circ_0080145/miR203/ABL1 and circ_0051886/miR-637/ABL1
Lu YH and Huang ZY. Mol Med, November 2021 – open access publication 
The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosis
Shoukier M et al. Haematologica, November 2021 – open access publication
Activated naïve gammadelta T cells accelerate deep molecular response to BCR-ABL inhibitors in patients with chronic myeloid leukemia
Chang YY et al. Blood Cancer J, November 2021 – open access publication 
Asciminib for CML: same target, new arrow
Schiffer CA Blood, November 2021
MS4A3 promotes differentiation in chronic myeloid leukemia by enhancing common ß chain cytokine receptor endocytosis
Zhao H et al. Blood, November 2021
(epub ahead of print
Taming the gatekeeper: ponatinib dose holds the key
Branford S Blood, November 2021
Age- and gender-independent association of XRCC1 polymorphism with chronic myeloid leukemia
Abdalhabib EK Int J Gen Med, November 2021 – open access publication 
Analyzing the impact of pregnancy on the outcomes of childbearing age women with chronic myeloid leukemia
Santos FM et al. Am J Hematol, November 2021
(epub ahead of print) – open access publication
Salidroside inhibits chronic myeloid leukemia cell proliferation and induces apoptosis by regulating the miR-140-5p/wnt5a/beta-catenin axis
Chen D and Luo C. Exp Ther Med, November 2021
– open access publication 
Statins enhance the molecular response in chronic myeloid leukemia when combined with tyrosine kinase inhibitors
Jang HJ Cancers (Basel), November 2021
(epub ahead of print)
Accurate machine-learning-based classification of leukemia from blood smear images
Dese K et al. Clin Lymphoma Myeloma Leuk, November 2021 
Risk factors for outcome after allogeneic stem cell transplantation in patients with advanced phase CML
Niederwieser C et al. Bone Marrow Transplant, November 2021 – open access publication
How to predict relapse in leukemia using time series data: A comparative in silicio study
Hoffmann H et al. PLoSOne, November 2021
– open access publication 
Asciminib as a new option in the treatment of chronic myeloid leukemia
Ibis B ete al. Future Oncol, November 2021 (epub ahead of print)
 
Monitoring and improving adherence to tyrosine kinase inhibitors in patients with chronic myeloid leukemia: A systematic review
Tan BK et al. Patient Prefer Adherence, November 2021
– open access publication
 
Safety and cost-effectiveness of ponatinib versus other tyrosine kinase inhibitors as second-line therapy in patients with chronic myeloid leukemia in the US
Yue X et al. Leuk Lymphoma, November 2021
(epub ahead of print)
 

Predictive value of clinical examination parameters for cardiovascular adverse events during treatment of chronic myeloid leukemia with tyrosine kinase inhibitors
Nakamae M et al. Int J Hematol, November 2021
(epub ahead of print)

 

A randomized, phase II trial of adjuvant immunotherapy with durable TKI-free survival in patients with chronic phase CML
Webster JA et al. Leuk Res, November 2021
(epub ahead of print)

 

A narrative review on adverse effects of dasatinib with a focus on pharmacotherapy of dasatinib-induced pulmonary toxicities
Nekoukar Z et al. Blood Res, November 2021
(epub ahead of print)
- open access publication

 
October 2021
Droplet digital PCR for BCR-ABL1 monitoring in diagnostic routine: Ready to start?
Bochiccio MT et al. Cancers (Basel), Oct 2021
– open access publication
Investigation on the interaction behaviour of afatinib, dasatinib, and imatinib docked to the BCR-ABL protein
Rocha KML eta l. J Mol Mode, October 2021 
Outcomes and toxicity of allogeneic hematopoietic cell transplantation in chronic myeloid leukemia patients previously treated with second-generation tyrosine kinase inhibitors: a prospective non-interventional study from the Chronic Malignancy Working Party of the EBMT
Masouridi-Levrat S et al. Bone Marrow Transplant, October 2021
(epub ahead of print)
– open access publication
Integrating genetic and epigenetic factors in chronic myeloid leukemia risk assessment: toward gene expression-based biomarkers
Krishnan V et a. Haematologica, October 2021
(epub ahead of print)
– open access publication
Making treatment-free remission (TFR) easier in chronic myeloid leukemia: Fact checking and practical management tools
Castagnetti F et al. Target Oncol, October 2021
(epub ahead of print)
- open access publication
Ultra-deep sequencing mutation analysis of the BCR/ABL1 kinase domain in newly diagnosed chronic myeloid leukemia patients
Park H et al. Leuk Res, October 2021
(epub ahead of print)
Prediction of cardiovascular events in patients with chronic myeloid leukemia using baseline risk factors and coronary artery calcium scoring
Baggio D et al. Intern Med J, October 2021
Small molecule inhibitor targeting the Hsp70-Bim protein-protein interaction in CML cells overcomes BCR-ABL-independent TKI resistance
Song T et al. Leukemia, October 2021
Imatinib plasma levels in patients with chronic myeloid leukemia under routine clinical practice conditions
Del Rosario García B et al. J Oncol Pharm Pract,
October 2021
JKST6, a novel multikinase modulator of the BCR-ABL1/STAT5 signalling pathway that potentiates direct BCR-ABL1 inhibition and overcomes imatinib resistance in chronic myelogenous leukemia
Aranda-Tavío H et al. Biomed Pharmacother,
October 2021 (epub ahead of print)
Pharmacokinetics of asciminib when taken with imatinib or with food
Hoch M et al. Clin Pharmacol Drug Dev,
October 2021 (epub ahead of print)
3D tissue engineered plasma cultures support leukemic proliferation and induces drug-resistance
Alhallah K et al. Leuk Lymphoma, October 2021 
Treatment-free remission: the new goal in CML therapy
Atallah E and Sweet K. Curr Hematol Malig Rep,
October 2021 (epub ahead of print)
– open access publication
Aberrantly reduced expression of miR-342-5p contributes to CCND1-associated chronic myeloid leukemia progression and imatinib resistance
Wu YY et al. Cell Death Dis, October 2021
(open access publication) 
The evolving landscape of frontline therapy in chronic phase chronic myeloid leukemia (CML)
Wolfe HR and Rein LAM. Curr Hematol Malig Rep, October 2021 (epub ahead of print)
 
The cure of leukemia through the optimist’s prism
Kantarjian HM et al. Cancer, October 2021
(epub ahead of print)
 
Novel BCR-ABL1 tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia
Malik S et al. Expert Rev Hematol, October 2021
(epub ahead of print)
 
Health-related quality of life of patients with chronic myeloid leukemia as measured by patient-reported outcomes: Current state and future directions
Schoenbeck KL and Flynn KE. Curr Hematol Malig Rep,
October 2021 (epub ahead of print)
 
Nilotinib-induced bone marrow CD34+/lin-Ph+ cells early clearance in newly diagnosed CP-chronic myeloid leukemia: Final report of the PhilosoPhi34 Study
Pungolino E et al. Eur J Hematol, October 2021
– open access publication
 
Serial evaluation of the pharmacokinetics of ponatinib in patients with CML and PH+ ALL
Kawano N et al. Int J Hematol, October 2021
 
Which tyrosine kinase inhibitors should be selected as the first-line treatment for chronic myelogenous leukemia in chronic phase?
Ono T. Cancers (Basel), October 2021 - open access publication
 
September 2021
Quality of life improvements in patients with chronic myeloid leukemia after stopping long-term therapy: who can benefit the most?
Efficace F and Baccarani M. J Natl Cancer Inst, September 2021 (epub ahead of print)
- open access publication
Genetic heterogeneity in chronic myeloid leukemia: How clonal hematopoiesis and clonal evolution may influence prognosis, treatment outcomes, and risk of cardiovascular events
Sant’Antonio E et al. Clin Lymphoma Myeloma Leuk, September 2021 
Patient-reported functional outcomes in patients with chronic myeloid leukemia after stopping tyrosine kinase inhibitors
Schoenbeck KL et al. J Natl Cancer Inst,
September 2021 (epub ahead of print)
Granulocyt and monocytic myeloid-derived suppressor cells are functionally and prognostically different in patients with chronic myeloid leukemia
Ahn A et al. Ann Lab Med, September 2021
– open access publication 
Chronic myeloid leukemia: Modern therapies, current challenges and future directions
Osman AEG and Deininger MW. Blood Rev,
September 2021
Association of creatine elevation with clinical outcomes in chronic myeloid leukemia: a retrospective cohort study
Bankar A and Lipton LH. Leuk Lymphoma, September 2021 (epub ahead of print) 
Long-term follow-up of frontline Dasatinib in older patients with chronic myeloid leukemia in chronic-phase treated outside clinical trials: a real-life cohort observational study
Stagno F et al. Acta Oncol, September 2021
(epub ahead of print)
Intracellular delivery of anti-BCR-ABL antibody by PLGA nanoparticles suppresses the oncogenesis of chronic myeloid leukemia cells
Jiang G et al. J Hematol Oncol, September 2021
– open access publication 
Second- or third-generation tyrosine kinase inhibitors in first-line treatment of chronic myeloid leukemia in general population: is there a real benefit?
Canet J et al. Cancer Med, September 2021
(epub ahead of print) – open access publication
BCR-ABL1 transcript doubling time as a predictor for treatment free remission after imatinib discontinuation in chronic myeloid leukemia
Kim DDH et al. Br J Hematol, September 2021
(epub ahead of print
Current evidence of the efficacy and safety of generic imatinib in CML and the impact of generics on health care costs
Erçaliskan A et al. Blood Adv, September 2021
- open access publication
Spred1 deficit promotes treatment resistance and transformation of chronic phase CML
Qiao J et al. Leukemia, September 2021
(epub ahead of print
How I treat chronic phase chronic myelogenous leukemia
Berman E et al. Blood, September 2021
(epub ahead of print)
Compromised anti-tumor-immune features of myeloid cell components in chronic myeloid leukemia patients
Harada I et al. Sci Rep, September 2021
– open access publication 
Chronic myeloid leukemia with pure erythroid leukemic blast crisis
Jacobs JW et al. Leuk Lymphoma, September 2021
(epub ahead of print)

PKC-beta/Alox5 axis activation promotes BCR-ABL-independent TKI-resistance in chronic myeloid leukemia
Ma D et al. J Cell Physiol, September 2021

Debating frontline therapy in chronic myeloid leukemia
Bi X et al. Front Oncol, September 2021
– open access publication
Mitochondrial metabolism as a potential therapeutic target in myeloid leukemia
de Breauchamp L et al. Leukemia, September 2021
(epub ahead of print)
- open access publication
Nilotinib versus Imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: 10-year follow-up of the Japanese subgroups of the randomized ENESTnd trial
Nakamae H et al. Int J Hematol, September 2021
(epub ahead of print)
 
Response to tyrosine kinase inhibitors in real-world patients with chronic myeloid leukemia
Szeto AH et al. Ann Pharmacother, September 2021
(epub ahead of print) – open access publication

 

 

Severe pleural effusion associated with nilotinib for chronic myeloid leukemia: cross-intolerance with tyrosine kinase inhibitors
Satoh K et al. BMJ Case Rep, September 2021

 
August 2021
A phase 3, open-label, randomized study of Asciminib, a STAMP inhibitor, vs Bosutininb in CML after ≥ prior TKI’s
Rea D et al. Blood, August 2021 (epub ahead of print)
ANP32B-mediated repression of p53 contributes to maintenance of normal and CML stem cells
Yang S et al. Blood, August 2021
(epub ahead of print
Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: A randomized, open-label phase 2 clinical trial
Cortes J et al. Blood, August 2021 (epub ahead of print)
Detection of mutations in CML patients resistant to tyrosine kinase inhibitor: imatinib msylate therapy
Karasu N et al. Med Oncol, August 2021
Chronic myeloid leukemia
Cortes J et al. Lancet, August 2021 (epub ahead of print)
Does eventually NPM1 mutation in blast phase chronic myeloid leukemia (BP-CML) exist? That is the question.
Henry A et al. Br J Haematol, August 2021
(epub ahead of print)
– open access publication 
Inotuzumab ozoganicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia
Jain N et al. Am J Hematol, August 2021
Molecular, cytogenetic, and haematological analysis of chronic myeloid leukemia patients and discovery of two novel translocations
Asif M et al. Anal Cell Pathol (Amst), August 2021
– open access publication 
Pulmonary hypertension in patients with chronic myeloid leukemia
Song IC et al. Medicine (Baltimore), August 2021
– open access publication 
CRISPR-Cas9 technology as a tool to target gene drivers in cancer: proof of concept and new opportunities to treat chronic myeloid leukemia
Vuelta E et al. CRISPR J, August 2021
Bosutinib in the real-life treatment of chronic myeloid leukemia patients aged > 65 years resistant/intolerant to previous tyrosine-kinase inhibitors
Latagliata R et al. Hematol Oncol, August 2021 

Genomic copy number variants in CML patients with the Philadelphia chromosome (Ph+): An update
Zhang H et al. Front Genet, August 2021
– open access publication

Extramedullary blast crisis in a chronic myeloid leukemia patient after achieving a major molecular response with bosutinib
Nakajima R et al. Br J Haematol, August 2021
(epub ahead of print) – open access publication
From the archives of MD Anderson Cancer Center: Concurrent BCR-ABL1 and CRLF2 rearrangements in B-lymphoblast phase of chronic myeloid leukemia
Thakral B et al. Ann Diagn Pathol, August 2021

Early prediction of stable MR(4.5) by depth of molecular response at 6 months in patients with chronic myeloid leukemia treated with frontline imatinib
Nee A et al. Leuk Lymphoma, August 2021 (epub ahead of print)

KIR3DL1 allotype-dependent modulations of NK cell immunity against chronic myeloid leukemia
Izumi K et al. Immunohorizons, August 2021
Asciminib: an investigational agent for the treatment of chronic myeloid leukemia
Breccia et al. Expert Opion Investig Drugs, August 2021
MiR-150 expression in chronic myeloid leukemia: Relation to imatinib response
Habib EM et al. Lab Med, August 2021 (epub ahead of print)
Is the Sokol or EUTOS long-term survival (ELTS) score a better predictor of responses and outcomes in persons with chronic myeloid leukemia receiving tyrosine-kinase inhibitors?
Zhang XS et al. Leukemia, August 2021
(epub ahead of print) – open access publication 
Pharmacologic targeting of the P-TEFb complex as a therapeutic strategy for chronic myeloid leukemia
Qing Y et al. Cell Commun Signal, August 2021
– open access publication
Tyrosine kinase inhibitor and vascular adverse events in chronic myeloid leukemia patients: a population-based, prospensity score-matched cohort study
Chen MT et al. Oncologist, August 2021
(epub ahead of print) – open access publication 
 
Long-term tolerability and efficacy after initial PegIFN- α addition to dasatinib in CML-CP – five year follow-up of the Nord CML007 study
Flygt H et al. Eur J Haematol, August 2021
(epub ahead of print) – open access publication 

Treatment free remission in patients with chronic myeloid leukemia: recommendations of LALNET expert panel
Pavlovsky C et al. Blood Adv, August 2021
(epub ahead of print) - open access publication
 
Treatment-free remission in chronic myeloid leukemia: Can we identify prognostic factors?
Scifullah HH and Lucas CM. Cancers (Basel),
August 2021 – open access publication

 

July 2021
Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukemia patients
Rousselot P et al. Br J Haematol, July 2021
TNF-α-induced alterations in stromal progenitors enhance leukemic stem cell growth via CXCR2 signalling
Agarwal P et al. Cell Rep, July 2021
– open access publication 
Fatigue in chronic myeloid leukemia patients on tyrosine kinase inhibitor therapy: predictors and the relationship with physical activity
Janssen L et al. Haematologica, July 2021
– open access publication
ND-09 inhibits chronic myeloid leukemia K562 cell growth by regulating BCR-ABL signalling
Liu YH et al. Oncol Rep, July 2021
– open access publication
 
Ophthalmologic manifestations as the initial presentation of chronic myeloid leukemia: A Review
Yassin MA et al. Surv Ophthalmol, July 2021
(epub ahead of print) – open access publication
Role of lysophospholipid metabolism in chronic myelogenous leukemia stem cells
Naka K. Cancers(Basel), July 2021
– open access publication 
Arterial hypertension assessment in a population with chronic myeloid leukemia
Roa-Chamorro R et al. Sci Rep, July 2021
– open access publication
DNA methylation and intra-clonal heterogeneity: The chronic myeloid leukemia model
Lebecque B et al. Cancers(Basel), July 2021
– open access publication
Thyroid autoimmunity and hypothyroidism are associated with deep molecular response in patients with chronic myeloid leukemia in tyrosine kinase inhibitors
Rodia R et al. J Endocrinol Invest, July 2021
(epub ahead of print) – open access publication
HNRNPH1 is a novel regulator of cellular proliferation and disease progression in chronic myeloid leukemia
Liu M et al. Front Oncol, July 2021
– open access publication
Efficacy and cardiovascular adverse events of long-term treatment with tyrosine kinase inhibitors for chronic myeloid leukemia: A Report from the Nagasaki CML Study Group
Chiwata M et al. Intern Med, July 2021
– open access publication
Profiles of NK cell subsets are associated with successful tyrosine kinase inhibitor discontinuation and changes following interferon treatment
Kong J et al. Ann Hematol, July 2021
(epub ahead of print)
Comparison of hepatotoxicity associated with new BCR-ABL tyrosine kinase inhibitors vs. imatinib among patients with chronic myeloid leukemia: A systematic review and meta-analysis
Wang Z et al. JAMA Netw open, July 2021
– open access publication
Hierarchical distribution of somatic variants in newly diagnosed chronic myeloid leukemia at diagnosis and early follow-up
Romzova M et al. Br J Haematol, July 2021
(epub ahead of print)
Impact of BCR-ABL1 transcript type on response, treatment-free remission rate and survival in chronic myeloid leukemia patients treated with imatinib
Marcé S et al. J Clin Med, July 2021
– open access publication
 
Quality of life among chronic myeloid leukemia patients in the second line treatment with nilotinib and influential factors
Nguyen CTT et al. Quali Life Res, July 2021
(epub ahead of print)
 
Correlates of fatigue severity in patients with chronic myeloid leukemia treated with targeted therapy
Oswald LB et al. Support Care Cancer, July 2021
(epub ahead of print)
 


June 2021

Impact of frontline treatment approach on outcome of myeloid blast phase CML
Saxena K et al. J Hematol Oncol, June 2021
open access publication

Allelic polymorphisms of KIRs and antitumor immunity against chronic myeloid leukemia
Shindo T et al. Immunol Med, June 2021
Long-term cardiac, vascular, hypertension, and effusion safety of bosutinib in patients with Philadelphia chromosome-positive leukemia resistant or intolerant to prior therapy
Cortes J et al. Eur J Haematol, June 2021
– open access publication
Gata2-L359V impairs primitive and definitive hematopoiesis nd blocks cell differentiation in murine chronic myelogenous leukemia models
Fu YK et al. Cell Death Dis, June 2021
– open access publication 
Measuring prognosis in chronic myeloid leukemia: What’s new?
Breccia M et al. Expert Rev Hematol, June 2021 (epub ahead of print)
Zfp36I1 plays an ambiguous role in the regulation of cell expansion and negatively regulates Cdkn1a in chronic myeloid leukemia cells
Kaehler M et al. Exp Hematol, June 2021 (epub ahead of print)
Treatment-free remission of chronic myeloid leukemia in real-world practice by the detected limit of MR4.3
Park P et al. Leuk Res, June 2021
Cytochrome P4502C19 gene polymorphisms (CYP2C19*2 and CYP2C19*3) in chronic myeloid leukemia patients: in vitro and in silico studies
Joshi K et al. J Biomol Struct Dyn, June 2021 (epub ahead of print)
Appropriate starting does of dasatinib based on analyses of dose-limiting toxicities and molecular responses in Asian patients with chronic myeloid leukemia
Shin H et al. Clin Lymphoma Myeloma Leuk, June 2021 
Multiplex technologies for the assessment of minimal residual disease and low-level mutation detection in leukemia: mass spectrometry versus next generation sequencing
Shanmunagathan N and Branford S. Br J Haematol,
June 2021 (epub ahead of print)
Asciminib: an investigational agent for the treatment of chronic myeloid leukemia
Breccia M et al. Expert Opin Investig Drugs, June 2021 (epub ahead of print)
Metabolic alterations mediated by STAT3 promotes drug persistence in CML
Patel SB et al. Leukemia, June 2021
(epub ahead of print) - open access publication
Subsequent attempt tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia; a single institute experience
Ureshino H et al. Hematol Oncol, June 2021
(epub ahead of print) 
CXCR2, a novel target to overcome tyrosine kinase inhibitor resistance in chronic myelogenous leukemia cells
Kim JH et al. Biochem Pharmacol, June 2021
(epub ahead of print)
Successful tyrosine kinase inhibitor discontinuation outside clinical trials – data from the population-based Swedish CML Registry
Flygt H et al. Br J Haematol, June 2021
– open access publication 
Assessment of droplet digital polymerase chain reaction for measuring BCR-ABL1 in chronic myeloid leukemia in an International interlaboratory study
Scott S et al. Br J Haematol, June 2021
(epub ahead of print) – open access publication
 Pharmakokinetics of Asciminib in individuals with hepatic or renal impairment
Hoch M et al. J Clin Pharmacol, June 2021
(epub ahead of print)
Positive interactions between STAP1 and BCR-ABL influences chronic myeloid leukemia cell proliferation and survival
Ishiura M et al. Biochem Biophys Res Comm, June 2021
Perspectives and emotional experiences of patients with chronic myeloid leukemia during ENESTPath clinical trial and treatment-free remission: Rationale and protocol of the Italian substudy
Borghi L et al. Front Oncol, May 2021
– open access publication

Targeting FEN1 suppresses the proliferation of chronic myeloid leukemia cells through regulating alternative end-joining pathways
Zhu Y et al. DNA Cell Biol, June 2021
(epub ahead of print)

 

Review of new-generation tyrosine kinase inhibitors for chronic myeloid leukemia
Shoukier M et al. Curr Oncol Rep, June 2021 

Brefeldin A induces apoptosis, inhibits BCR-ABL activation, and triggers BCR-ABL degradation in CML K562 cells
Zhang JM et al. Anticancer Agents Med Chem, June 2021 (epub ahead of print)
Nilotinib induced bone marrow CD34+/lin-Ph+ cells early clearance in newly diagnosed CP-chronic myeloid leukemia: final report of the PhilosoPhi34 study
Pungolino E et al. Eur J Haematol, June 2021
(epub ahead of print)
Targeting HSPA8 inhibits proliferation via downregulating BCR-ABL and enhances chemosensitivity in imatinib-resistant chronic myeloid leukemia cells
Liu Z et al. Exp Cell Res, June 2021
(epub ahead of print)
May 2021
Long-term treatment-free remission in patients with chronic myeloid leukemia after second-line nilotinib. ENESTop 5-year update
Hughes TP et al. Leukemia, May 2021
(epub ahead of print)
Target spectrum of the BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemic
Lee H et al. Int J Hematol, May 2021
Why chronic myeloid leukemia cannot be cured by tyrosine kinase inhibitors
Baccarani M and Gale RP. Leukemia, May 2021
(epub ahead of print)
Suppression of USP1 induces BCR-ABL degradation and chronic myelogenous leukemia cell apoptosis
Jiang S et al. Cell Death Dis, May 2021
open access publication 
EUTOS long-term survival score discriminated different SOKAL score categories in chronic myeloid leukemia patients, showing better survival prediction. Analysis of the GIMEMA CML observational study
Breccia M et al. Leukemia, May 2021
(epub ahead of print)
Mutational landscape of chronic myeloid leukemia: more than a single oncogene
Adnan-Awad S et al. Leuk Lymphoma, May 2021
(epub ahead of print
Budget impact of tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia with sustained deep molecular response
Astruge C et al. Value Health, May 2021
Understanding the hematopoietic microenvironment in chronic myeloid leukemia: A concise review
Torres-Barrera P et al. Curr Res Transl Med, May 2021 (epub ahead of print) 
Relevance of treatment-free remission recommendations in chronic phase chronic myeloid leukemia patients treated with frontline tyrosine kinase inhibitors
Etienne G et al. Cancer Med, May 2021
(epub ahead of print) – open access publication  

Validation of CIP2A as a biomarker of subsequent disease progression and treatment failure in chronic myeloid leukemia
Clark RE et al. Cancers(Basel), May 2021
open access publication

Evaluation of two CE-IVD tests for BCR-ABL1 transcript monitoring of chronic myeloid leukemia patients
Folta A et al. Leuk Lymphoma, May 2021 
Clonal evolution and clinical implications of genetic abnormalities in blastic transformation in chronic myeloid leukemia
Ochi Y et al. Nat Commun, May 2021
open access publication
Promyelocytic blast phase of chronic myeloid leukemia; BCR-ABL1 positive: Points to be considered at diagnosis
Kim B et al. Ann Lab Med, May 2021
open access publication 
Sirtuin1 and chronic myeloid leukemia: A comprehensive glance of drug resistance
Abbasian S et al. Clin Lab, May 2021
Adverse events among chronic myelogenous leukemia patients treated with tyrosine kinase inhibitors: A real-world analysis of health plan enrolees
Chow EJ et al. Leuk Lymphoma, May 2021 
 
An indirect comparison between bosutinib, nilotinib and dasatinib in chronic phase chronic myeloid leukemia
Muresan B et al. Curr Med Res Opin, May 2021
(epub ahead of print) 
 
Overcoming TKI resistance in a patient with chronic myeloid leukemia using combination BCR-ABL inhibition with asciminib and bosutinib
Hall KH et al. Am J Hematol, May 2021
(epub ahead of print) – open access publication 
 
Current status and novel strategy for CML
Morita K and Sasaki K. Int J Hematol, May 2021 
 
April 2021
Asciminib in chronic myeloid leukemia: Many questions still remain to be answered
Eskazan AE. Blood Cancer J, April 2021
open access publication 

Recent advances in understanding chronic myeloid leukemia: Where do we stand?
Kumar R and Krause DS. Fac Rev, April 2021
open access publication

Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia treated with hyper-CVAD and dasatinib
Morita K et al. Cancer, April 2021 (epub ahead of print)
Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape
Hsieh YC et al. Leukemia, April 2021
(epub ahead of print) – open access publication
Survival of chronic myeloid leukemia patients in comparison to the general population in the tyrosine kinase inhibitors era: A US population based study
Jamy O et al. Am J Hematol, April 2021
(epub ahead of print) - open access publication
Tackling resistance in chronic myeloid leukemia: Novel cell death modulators with improved efficacy
Schoepf AM et al. Eur J Med Chem, April 2021
– open access publication
Optimal duration of imatinib treatment/deep molecular response for treatment-free remission after imatinib discontinuation from a Canadian tyrosine kinase inhibitor discontinuation trial
Kim DDH et al. Br J Haematol, April 2021
(epub ahead of print)
An aging mouse model of human chronic myeloid leukemia
Hao T et al. Oncogene, April 2021 (epub ahead of print)
Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trial
Chuah C et al. Int J Hematol, April 2021
(epub ahead of print)
Repositioning antispasmodic drug papaverine for the treatment of chronic myeloid leukemia
Parcha PK et al. Pharmacol Rep, April 2021
Bosutinib-related pleural effusion in patients with chronic myeloid leukemia
Yüzbasloglu MB and Eskazan AE. Expert Opin Drug Saf, April 2021
The regulation of bcr-abl in hypoxia is through the mTOR pathway
Clapper E et al. Leuk Lymphoma, April 2021
Real-life evaluation of potential candidates for treatment discontinuation in chronic myeloid leukemia: the impact of age and long-term follow-up
Scalzulli E et al. Leuk Lymphoma, April 2021
Leukemic stem cells shall be searched in the bone marrow before tyrosine kinase inhibitor-discontinuation in chronic myeloid leukemia
Ilhan O et al. Int J Lab Hematol, April 2021 (epub ahead of print)
When to stop TKIs in patients with chronic myeloid leukemia and how to follow them subsequently
Cerveira N et al. Curr Treat Options Oncol, April 2021
Rare monosomy 7 and deletion 7p at diagnosis of chronic myeloid leukemia in accelerated phase
Alswied A et al. Cancer Genet, April 2021
Interventions to improve adherence to tyrosine kinase inhibitors in chronic myeloid leukemia: A systematic review
Heiney SP et al. Am J Clin Oncol, April 2021
(epub ahead of print)
 
March 2021
Dosing strategies for improving the risk-benefit profile of ponatinib in patients with chronic myeloid leukemia in chronic phase
Castagnetti F et al. Front Oncol, March 2021
– open access publication
Targeting chronic myeloid leukemia stem/progenitor cells using Venetoclax-loaded immunoliposome
Houshmand M et al Cancers(Basel), March 2021
– open access publication
Third-line therapy for chronic myeloid leukemia: Current status and future directions
Cortes J and Lang F. J Hematol Oncol, March 2021 – open access publication
Smoothened inhibitor erismodegib combined with nilotinib in patients with chronic myeloid leukemia resistant/intolerant to at least one prior tyrosine kinase inhibitor: a phase 1b study
Ottmann OG et al. Leuk Lymphoma, March 2021 
Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial
Radich JP et al. Leukemia, March 2021
(epub ahead of print)
– open access publication
Treatment-free remission and immunity in chronic myeloid leukemia
Ureshino H. Int J Hematol, March 2021
(epub ahead of print
Asessment of individual molecular response in chronic myeloid leukemia patients with atypical BCR-ABL1 fusion transcripts: recommendations by the EUTOS cooperative network
Schäfer V et al. J Cancer Res Clin Oncol, March 2021 (epub ahead of print)
– open access publication
New routes to eradicating chronic myelogenous leukemia stem cells by targeting metabolism
Naka K. Int J Hematol, March 2021
(epub ahead of print
Tyrosine kinase inhibitor therapy discontinuation in patients with chronic myeloid leukemia in chronic phase in the United States after clinical practice guideline updates
Atallah EL et al. Leuk Lymphoma, March 2021
(epub ahead of print)
Efficiency of nilotinib to target chronic-phase chronic myeloid leukaemia primary mature CD34- and immature CD34+ cells
Berger MG et al. Sci Rep, March 2021
– open access publication 

The safety and efficacy of dasatinib plus nivolumab in patients with previously treated chronic myeloid leukemia: results from a phase 1b dose-escalation study
Martínez-López J et al. Leuk Lymphoma, March 2021 (epub ahead of print)

The discovery of novel BCR-ABL tyrosine kinase inhibitors using a pharmacophore modelling and virtual screening approach
Huang TT et al. Front Cell Dev Biol, March 2021 – open access publication 
I rock the boat? When to stop TKI’s in CML?
Nazha A. Blood, March 2021
Discovery of a novel CIP2A variant (NOCIVA) with clinical relevance in predicting TKI resistance in myeloid leukemias
Makela E et al. Clin Cancer Res, March 2021
(epub ahead of print)
– open access publication 
Long-term follow-up of late chronic phase chronic myeloid leukemia patients treated with imatinib after interferon failure: a single center experience
Pepe S et al. Leuk Lymphoma, March 2021
(epub ahead of print)
Proteasome 26S subunit, non-ATPases 1 (PSMD1) and 3 (PSMD3), play an oncogeneic role in chronic myeloid leukemia by stabilizing nuclear factor-kappa B
Bencome-Alvarez AE, Oncogene, March 2021
(epub ahead of print)
– open access publication
Ponatinib long-term follow-up of efficacy and safety in CP-CML patients in real world setting in France: The POST-PACE study
Etienne G et al. Leuk Res, March 2021 (epub ahead of print)

Epigenetic and functional changes imposed by NUP98-HOXA9 in a genetically engineered model of CML progression
Sloma I et al. Haematologica, March 2021
– open access publication

Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients
Scalzulli E et al. Ann Hematol, March 2021
(epub ahead of print)

 
arly BCR-ABL kinetics are predictive of subsequent achievement of treatment-free-remission in CML
Shanmunagathan N et al. Blood, March 2021 
 
February 2021
Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKI’s: First interim analysis of OPTkIMA study
Malagola M et al. Cancer Med, February 2021
(epub ahead of print)
- open access publication
Additional chromosomal abnormalities at chronic myeloid leukemia diagnosis predict an increased risk of progression
Clark RE et al. Blood Adv, February 2021
- open access publication
Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR – final report from AFTER-SKI
Richter J et al. Leukemia, February 2021
(epub ahead of print)
– open access publication
Eradicating residual chronic myeloid leukemia: basic research lost in translation
Zhao H and Deininger M. Lancet Haematol, February 2021
Mortality rates in patients with chronic myeloid leukemia in chronic phase with frontline second generation kinase inhibitors: a retrospective analysis by the monitoring registries of the Italian Medicines Agency (AIFA)
Breccia M et al. Ann Hematol, February 2021
Exosomes released by imatinib-resistant K562 cells contain specific membrane markers, IFTM3, CD146 and CD36 and increase the survival of imatinib-sensitive cells in the presence of imatinib
Hrdinova T et al. Int J Oncol, February 2021
Dose-optimization of tyrosine kinase inhibitors in chronic myeloid leukemia: A new therapeutic challenge
Iurlo A et al. J Clin Med, February 2021 – open access publication
 

Assessment of azithromycin as an anticancer agent for treatment of imatinib sensitive and resistant CML cells
Ozkan T et al. Leuk Res, February 2021
(epub ahead of print)

Bosutinib in the real-life treatment of chronic myeloid leukemia patients >65 years resistant/intolerant to previous tyrosine-kinase inhibitors
Latagliata R et al. Hematol Oncol, February 2021
(epub ahead of print)
Circulating miR-1461 expression to imatinib in adult chronic myeloid leukemia
Habib EM et al. J Investig Med, February 2021
Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice
Garcia-Gutiérrez V et al. Blood Cancer J, February 2021
– open access publication
Future approaches for treating chronic myeloid leukemia: CRISP therapy
Vuelta E et al. Biology(Basel), February 2021
– open access publication

MR4 log and low levels of NK cells are associated with higher molecular relapse after imatinib discontinuation: Results of a prospective trial
Seguro FS et al. Leuk Res, February 2021

Targeting of plasminogen activator inhibitor-1 activity promotes elimination of chronic myeloid leukemia stem cells
Yahata T et al. Haematologica, February 2021
– open access publication
Optimizing health-related quality of life in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors
Efficace F et al. Expert Rev Hematol, February 2021
(epub ahead of print)
Co-existence of BCR-ABL and JAK2V617F mutation in resistant chronic myeloid leukemia in the imatinib era: is there a correlation?
Frikha R et al. J Oncol Pharm Pract, February 2021
(epub ahead of print)
ong-term cardiac, vascular, hypertension, and effusion safety of bosutinib in patients with Philadelphia chromosome-positive leukemia resistant or intolerant to prior therapy
Cortes JE et al. Eur J Haematol, February 2021
(epub ahead of print
The prognostic importance of BCR-ABL transcripts in chronic myeloid leukemia: A systematic review and meta-analysis
Ghalesardi OK et al. Leuk Res, February 2021
  Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML)
Lu T et al. Eur J Pharmacol, February 2021
(epub ahead of print)
January 2021
Clinical outcomes of patients with chronic myeloid leukemia with concurrent core binding factor rearrangement and Philadelphia chromosome
Morita K et al. Clin Lymphoma Myeloma Leuk,
January 2021 (epub ahead of print)
The giant HECT E3 ubiquitin ligase HERC1 is aberrantly expressed in myeloid related disorders and it is a novel BCR-ABL1 binding partner
Ali MS et al. Cancers(Basel), January 2021
– open access publication 
Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed CML in chronic phase: ENESTnd 10-year analysis
Kantarjian HM et al. Leukemia, January 2021
(epub ahead of print) – open access publication  
Genetic screening for potential new targets in chronic myeloid leukemia based on Drosophia Transgenic for human BCR-ABL
Lo Iacono M et al. Cancers(Basel), January 2021
– open access publication 
ILong-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukemia: results from the French SPIRIT phase III randomised trial
Guilhot F et al. Leukemia, January 2021
(epub ehead of print)
The quiescent fraction of chronic myeloid leukemia stem cells depends on BMPR1B, STAT3, and BMP4-niche signals to persistent in patients in remission
Jeanpierre S et al. Haematologica, January 2021
– open access publication 
Digital droplet PCR as a predictive tool for successful discontinuation outcome in chronic myeloid leukemia: Is it time to introduce it in the clinical practice?
Colafigli G et al. Crit Rev Oncol Hematol, January 2021
HLA polymorphis are associated with treatment-free remission following discontinuation of TKI’s in CML
Ureshino H et al. Mol Cancer Ther, January 2021 
Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia in patients treated with nilotinib
Caocci G et al. Ann Hematol, January 2021
(epub ahead of print)
Combating TKI resistance in CML by inhibiting the PI3K/Akt/mTor pathway in combination with TKIs: A review
Singh P et al. Med Oncol, January 2021
Treatment patterns and clinical outcomes of tyrosine kinase inhibitors in chronic-phase CML in clinical practice: 3-year European SIMPLICITY data
Gambarcoti-Passerini C et al. Eur J Haematol, January 2021 – open access publication
The BCRP inhibitor febuxostat enhances the effect of nilotinib by regulation of intracellular concentration
Ito F et al. Int J Hematol, January 2021 
Adherence, persistence and efficacy of dasatinib and nilotinib in the treatment of patients resistant or intolerant to imatinib with chronic myeloid leukemia in chronic phase: an Italian multicenter study over two years in real-life
Santoleri F et al. Curr Med Res Opin, January 2021
(epub ahead of print)
NT157, an IGF1R-IRS1/2 inhibitor exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia
Scopim-Ribeiro R et al. Invest New Drugs, January 2021 (epub ahead of print)
Real-world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukemia in the United Kingdom: the UK TARGET CML study
Milojkociv D et al. Br J Haematol, January 2021
– open access publication


BCR-ABL kinase domain mutation analysis by Next Generation Sequencing detected additional mutations in CML patients with suboptimal response to Nilotinib
Benjamin ESB et al. Leuk Lymphoma, January 2021
(epub ehead of print)
 


CML Publications 2014-2020

Access 2020 CML publications here
Access 2019 CML publications here
Access 2018 CML publications here
Access 2017 CML publications here
Access 2016 CML publications here
Access 2015 CML publications here
Access 2014 CML publications here


Would you like to suggest an interesting paper or article? >> Please provide us with the details here and we will be happy to review your suggestion!

Search for more publications on CML at PubMed.gov

 

 

Publications on COVID-19 and CML/Cancer - 2021

December 2021

November 2021

October 2021

September 2021

August 2021

July 2021

June 2021

May 2021

April 2021

March 2021

February 2021

January 2021

The Board of Directors of the iCMLf:

iCMLf t shirt Women

iCMLf T shirt

CD5171 FunRun Run Ride Cure RED 01

 

 

 

 

 

 

 

 

Visit our iCMLf charity t-shirt store - International
to get your 2021 Run.Ride.Cure t-shirt or hoodie shipped to EU/US and International

All profits will contribute to the iCMLf global research accelerating the development of more effective and safer treatment strategies for people with CML.

Read more about shopping procedures:

Your contribution supports research in CML and helps to make cure a reality for patients with CML one day.

Please donate now to drive research in CML.

Over the past decades, significant advances have been made in the treatment and monitoring of CML. But a cure for CML is still an unmet need.

“A concerted global effort working towards a cure is imperative. The iCMLf is uniquely positioned to drive this effort.”
– Tim Hughes, iCMLf Chairman

The iCMLf has launched global research collaborations to accelerate the development of more effective and safer treatment strategies with the view that ultimately these will lead to a cure for CML.

Learn more about the iCMLf CURE Consortium here

Our mission is to improve the outcomes for patients with CML globally.

Let's work together on this to drive research on a cure for CML.

Every contribution counts

Please note: fields marked with a star (*) are required.

Donate by Credit Card

Use this form to make an online donation. If this is for something specific, please note that in the comment box

Your Details


Donation

USD$
/

CML Publications 2020

Clinical Publications Scientific Publications
December 2020
TKI dose reduction can effectively maintain major molecular remission in patients with chronic myeloid leukemia
Claudiani S et al. Br J Haematol, December 2020 (epub ahead of print
Identification of immunological parameters as predictive biomarkers of relapse in patients with chronic myeloid leukemia on treatment-free remission
Vigón L et al. J Clin Med, December 2020
– open access publication 
Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: When and for whom?
Atallah E and Schiffer CA. Haematologica, December 2020 – open access publication
Targeting of the Alox12-12-HETE in blast crisis chronic myeloid leukemia inhibits leukemia stem/progenitor cell function
(Gao S et al. Cancer Manag Res, December 2020)
– open access publication 

Why is it critical to achieve a deep molecular remission in chronic myeloid leukemia?
Branford S. Haematologica, December 2020
– open access publication

Inhibitors targeting STAT5 signaling in myeloid leukemias: New Tetrahydroquinoline derivates with improved antileukemic potential
(Prié G et al. ChemMedChem, December 2020
BCR-ABL1 compound mutants: prevalence, spectrum and correlation with tyrosine kinase inhibitor resistance in a consecutive series of Philadelphia chromosome-positive leukemia patients analysed by NGS
(Soverini S et al. Leukemia, December 2020)
(epub ahead of print)
Let-7b regulates the Adriamycin resistance of chronic myelogenous leukemia by targeting AURKB in K562/ADM cells
(Zhou X etc. Leuk Lymphoma, December 2020
First-generation vs second-generation tyrosine kinase inhibitors: which is best at diagnosis of chronic-phase chronic myeloid leukemia
(Oehler VG. Hematology Am Soc Hematol Educ Program, December 2020)
– open access publication
Evidence that knock down of GSK-3beta in chronic myelogenous leukemia cells augments IFN-gamma-induced apoptosis
(Kauffmann MR et al. Leuk Res, December 2020
Tyrosine kinase inhibitor discontinuation in the management of chronic myeloid leukemia: a critical review of the current practice
(Breccia M et al. Expert Rev Hematol, December 2020)
Expansion of senescent megakaryocyte-lineage cells maintains CML cell leukemogenesis
(Tanabe Y et al. Blood Adv, December 2020)
– open access publication 
Efficacy and safety of pioglitazone in a phase 1/2 imatinib discontinuation trial (EDI-PIO) in chronic myeloid leukemia with deep molecular response
(Pagnano KBB et al. Am J Hematol, December 2020) – open access publication

Novel strategies to eradicate resistant cells in chronic myeloid leukemia
(Schopf AM and Gust R. Future Med Chem, December 2020)

Management of chronic myeloid leukemia during pregnancy among patients with tyrosine kinase inhibitor:
a single-Centre experience
(Assi R et al. Leuk Lymphoma, December 2020)
(epub ahead of print)

Widespread aberrant alternative splicing despite molecular remission in chronic myeloid leukaemia patients
(Schmitz U et al. Cancers (Basel), December 2020)
– open access publication

Quality of life and symptom burden with first- and second generation tyrosine kinase inhibitors in patients with chronic-phase chronic myeloid leukemia
(Boston H et al. Clin Lymphoma Myeloma Leuk, December 2020)

Circadian clock gene Period2 suppresses human chronic myeloid leukemia cell proliferation
(Wang N et al. Exp Ther Med, December 2020)
– open access publication

Switch from branded to generic imatinib: impact on molecular responses and safety in chronic-phase chronic myeloid leukemia patients
(Scalzulli E et al. Ann Hematol, December 2020)

 

Pregnancy outcomes of women whom spouse fathered children after tyrosine kinase inhibitor therapy for CML:
A systematic review
(Szakács Z et al. PLoS One, December 2020)
– open access publication

 

Impact of anemia on the outcomes of chronic phase chronic myeloid leukemia in TKI era
(Liu Z et al. Hematology, December 2020)

 
November 2020
How to manage CML patients with comorbidities
(Cortes J. Blood, November 2020)
– open access publication
Characterization of p190 BCR-ABL chronic myeloid leukemia reveals specific signalling pathways and therapeutic targets
(Adnan-Awad S et al. Leukemia, November 2020)
(epub ahead of print
Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia
(Abaza Y et al. Am J Hematol, November 2020)
P19INK4d inhibits proliferation and enhances imatinib efficacy through BCR-ABL signalling pathway in CML
(Kuang Y et al. Blood Cells Mol Dis, November 2020)  
Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: Updates from the LAST study on patient-reported outcomes and biomarkers for relapse
(Braun TP and Druker BJ. JAMA Oncol, November 2020)
AMD1 is required for the maintenance of leukemia stem cells and promotes chronic myeloid leukemic growth
(Sari IN et al. Oncogene, November 2020)
(epub ahead of print)  
The LEukemia Artificial Intelligence Program (LEAP) in chronic myeloid leukemia in chronic phase: A model to improve patient outcomes
(Sasaki K et al. Am J Hematol, November 2020)
(epub ahead of print)
The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase
(Manley PW et al. Leuk Res, November 2020)
Assessment of outcomes after stopping tyrosine kinase inhibitors among patients with chronic myeloid leukemia: A nonrandomized clinical trial
(Atallah E et al. JAMA Oncol, November 2020)
(epub ahead of print)
 
Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: update form the LAST study on patient-reported outcomes and biomarkers for relapse
(Braun TP and Druker BJ. JAMA Oncol, November 2020) (epub ahead of print)
 
Handling challenging questions in the management of chronic myeloid leukemia: When is it safe to stop tyrosine kinase inhibitors?
(Rea D. Blood Adv, November 2020)
– open access publication
 
Increased tumor burden in patients with CML after 36 months of imatinib discontinuation
(Diral E et al. Blood, November 2020)
 
There is a best duration of deep molecular response for treatment-free remission, but it is patient-specific, and that is the challenge
(Ross DM and Hughes TP. Br J Haematol, November 2020) (epub ahead of print
 
Validation and reference values of the EORTC QLQ-CML24 questionnaire to assess health-related quality of life in patients with chronic myeloid leukemia
(Efficace F et al. Leuk Lymphoma, November 2020)
(epub ahead of print)
 
Predictors of tyrosine kinase inhibitor adherence trajectories in patients with newly diagnosed chronic myeloid leukemia
(Clark SE et al. J Oncol Pharm Pract, November 2020)
(epub ahead of print)
 

Standardization of BCR-ABL1 p210 monitoring: From nested to digital PCR
(Jovanovski A et al. Cancers (Basel), November 2020)
– open access publication

 
Point: Is there a best duration of deep molecular response to achieve therapy-free remission in chronic myeloid leukemia?
(Gale RP and Saglio G. Br J Haematol, November 2020)
(epub ahead of print)
 
A retrospective analysis about frequency of monitoring in Italian chronic myeloid leukemia patients after discontinuation
(Dragani M et al. J Clin Med, November 2020)
– open access publication
 
Tyrosine kinase inhibitor treatment discontinuation in CML: patient views
(Tromp VNMF et al. Leuk Lymphoma, November 2020)
(epub ahead of print)
– open access publication
 
October 2020
Tyrosine kinase inhibitors and pregnancy in chronic myeloid leukemia: opinion, evidence and recommendations
(Abruzzese E et al. Ther Adv Hematol, October 2020) - open access publication
Recent advances in BCR-ABL tyrosine kinase inhibitors for overriding T315I mutation
(Liu J et al. Chem Biol Drug Des, October 2020)
(epub ahead of print
Comparison of droplet digital PCR versus qPCR measurements on the International Scale for the molecular monitoring of chronic myeloid leukemia patients
(Cortés AA et al. Mol Diagn Thera, October 2020)
Delineation of target expression profiles in CD34+/CD38- and CD34+/CD38+ stem cell and progenitor cells in AML and CML
(Herrmann H et al. Blood Adv October 2020)
– open access publication
The EUTOS long-term survival score predicts disease-specific mortality and molecular responses among patients with CML in a practice-based cohort
(Sato E et al. Cancer Med, October 2020)
(epub ahead of print)
- open access publication  
Increased expression of TIGIT/CD57 in peripheral blood/bone marrow NK cells in patients with chronic myeloid leukemia
(Yao D et al. Biomed Res Int, October 2020)
– open access publication
Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when and for whom?
(Atallah E and Schiffer CA. Haematologica, October 2020) – open access publication
AMP-activated protein kinase activation primes cytoplasmic translocation and authophagic degradation of the BCR-ABL protein in CML cells
(Koyama D et al. Cancer Sci, October 2020)
(epub ahead of print)
– open access publication
Chronic myeloid leukemia, Version 2.2021, NCCN Clinical Practice Guidelines
(Deininger MW et al. J Natl. Compr Canc Netw, October 2020) – open access publication
In vitro comparison of the effects of imatinib and ponatinib on chronic myeloid leukemia progenitor/stem cell features
(Tusa I et al. Target Oncol, October 2020)
– open access publication
Chronic myeloid leukemia in solid organ transplant patients: a case series
(Amitai I et al. Int J Hematol, October 2020)
(epub ahead of print)
PD-1 expressing CD56-negative NK cell expansion is a hallmark of chronic NK cell activation during dasatinib treatment
(Ishiyama KI et al. Cancer Sci, October 2020)
(epub ahead of print) – open access publication
Treatment outcomes in chronic myeloid leukemia: Does one size fit all?
(Garcia-Horton A and Lipton JH. J Natl Compr Canc Netw, October 2020) – open access publication
CytoGPS: A large-scale karyotype analysis of CML data
(Abrams ZB et al. Cancer Genet, October 2020)
(epub ahead of print)
Favourable outcome of chronic myeloid leukemia co-expressing e13a2 and e14a2 transcripts, treated with nilotinib
(Mulas O et al. Hematol Oncol, October 2020)
Elucidation of protein interactions necessary for the maintenance of the BCR-ABL signalling complex
(Gregor T et al. Cell Mol Sci, October 2020)
On the road to treatment-free remission in chronic myeloid leukemia: What about ‘the others’?
(Stagno F et al. Expert Rev Anticancer Ther, October 2020) (epub ahead of print)
DYRK2 controls a key regulatory network in chronic myeloid leukemia
(Park CS and Lacorazza HD. Exp Mol Med, October 2020)
(epub ahead of print)
- open access publication
Case series of chronic myeloid leukemia patients who maintained deep molecular response (DMR) with very low-dose ponatinib: experience in discontinuing low-dose ponatinib and treatment-free remission (TFR) outcomes
(Cohen J et al. Leuk Lymphoma, October 2020)
Detection of residual disease in CML utilizing genome next generation sequencing reveals persistence of differentiated Ph(+) B cells but not bone marrow/stem progenitors
(Karigane D et al. Leuk Lymphoma, October 2020)
(epub head of print)
Dasatinib treatment long-term results among imatinib-resistant/intolerant patients with chronic phase chronic myeloid leukemia are favourable in daily clinical practice
(Zackova D et al. Leuk Lymphoma, October 2020)
(epub ahead of print)
Examination of clinically-derived p210 BCR/ABL1 RhoGEF mutations in a murine model marrow transplantation of CML
(Ciccarelli BT et al. Leuk Res, October 2020)
September 2020
Why is it critical to achieve a deep molecular response in chronic myeloid leukemia?
(Branford S. Haematologica, September 2020) – open access publication
CML – Not only BCR-ABL1 matters
(Rinke J et al. Best Pract Res Clin Haematol, September 2020)
Breakpoints mapping of a t(9;22;12) chronic myeloid leukemia patient with e14a3 BCR-ABL1 transcript using nanopore sequencing
(Zhao H et al. J Gene Med, September 2020)
(epub ahead of print
Declaration of BCR-ABL1 independence
(Zhao H and Deininger MW. Leukemia, September 2020)
Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia
(Shanmunagathan N et al. Blood, September 2020) (epub ahead of print)
Efficacy of tyrosine kinase inhibitors on a mouse chronic myeloid leukemia model and chronic myeloid leukemia stem cells
(Tanaka Y et al. Exp Hematol, September 2020
Incidence of deep molecular responses and treatment-free remission in de novo CP-CMO patients
(Etienne G et al. Cancers(Basel), September 2020)
– open access publication
Checkpoint kinase-1 inhibitors and etoposide exhibit a strong synergistic anticancer effect on chronic myeloid leukemia cell line K562 by impairing homologenous recombination DNA damage repair
(Fan Z et al. Oncol Rep, September 2020)
(epub ahead of print)
- open access publication 
Erythropoietin treatment in chronic myeloid leukemia patients treated with frontline imatinib who developed anaemia
(Cesini L et al. Eur J Hematol, September 2020)
A novel HDAC inhibitor chidamide combined with imatinib synergistically targets tyrosine kinase inhibitor chronic myeloid leukemia cells
(He B et al. Biomed Pharmacother, September 2020)
– open access publication 
Treatment-free remission in chronic myeloid leukemia harbouring atypical BCR-ABL1 transcripts
(Dragani M et al. Mediterr J Hematol Infect Dis, September 2020)
– open access publication
BCR-ABL allosteric inhibitors: Where we are and where we are going to
(Carofiglio F et al. Molecules, September 2020)
– open access publication 
Unravelling surviving expression in chronic myeloid leukemia: Molecular interactions and clinical implications
(Bernardo PS et al. Blood Rev, September 2020)
 
Second-line dasatinib therapy improved compliance and deep molecular responses in imatinib-intolerant chronic myeloid leukemia patients
(Markovic U et al. Anticancer Res, September 2020)
 
Impact of the BCR-ABL1 transcript type on clinical and biological parameters and molecular response in patients with chronic myeloid leukemia
(Nachi M et al. Hematol Oncol Stem Cell Ther, September 2020)
– open access publication
 
Response and adherence to nilotinib in daily practice (RAND study): an in-depth observational study of chronic myeloid leukemia patients treated with nilotonib
(Boons CCLM et al. Eur J Pharmacol, September 2020)
– open access publication
 
August 2020
Moving on from 2013 to 2020 European LeukemiaNet recommendations for treating chronic myeloid leukemia: what has changed over the 7 years?
(Yilmaz U & Eskazan AE. Expert Rev Hematol, August 2020)
(epub ahead of print)
- open access publication
SIRT7: an influence factor in healthy aging and the development of age-dependent myeloid stem cell disorders
(Kaiser A et al. Leukemia, August 2020
A phase 1 study to evaluate the feasibility and efficacy of the addition of ropeginterferon alpha-2b to imatinib in patients with chronic phase chronic myeloid leukemia (CML) not achieving a deep molecular response (molecular remission 4.5) – AGMT-CML1
(Heibl S et al. Hematol Oncol, August 2020)
(epub ahead of print)
RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responses
(Adnan Awad S et al. Leukemia, August 2020) (epub ahead of print)
– open access publication
Treatment-free remission in chronic myeloid leukemia: the patient perspective and areas of unmet needs
(Sharf G et al. Leukemia, August 2020)
– open access publication
Signal-transducing adapter protein-1 is required for maintenance of leukemic stem cells in CML
(Toda J et al. Oncogene, August 2020)
– open access publication
Low-dose tyrosine kinase inhibitors before treatment discontinuation do not repair treatment-free remission in chronic myeloid leukemia patients: Results of a retrospective study
(Cayassials E et al. Cancer, August 2020)
– open access publication 
A high-content cytokine screen identifies myostatin propeptides as a positive regulator of primitive chronic myeloid leukemia cells
(von Palffy S et al. Haematologica, August 2020) – open access publication
Epidural myeloid sarcoma a the presenting symptom of chronic myeloid leukemia blast crisis
(Slouma M et al. Clin Rheumatol, August 2020) – open access publication
Nuclear receptors as potential therapeutic targets for myeloid leukemia
(Pan P & Chen X. Cells, August 2020)
Ponatinib therapy in recurrent Philadelphia chromosome-positive central nervous system leukemia with T315I mutation after Allo-HSCT
(He JB et l. Int J Cancer, August 2020)
– open access publication
In vitro comparison of the effects of imatinib and ponatinib on chronic myeloid leukemia progenitor/stem cell features
(Tusa I et al. Target Oncol, August 2020)
(epub ahead of print)
– open access publication
Vascular events may predict the prognosis of patients with chronic myeloid leukemia
(Ureshino H & Kamachi K. Int J Hematol, August 2020)
– open access publication
Characterization of several leukemia-associated antigens inducing humoral immune responses in acute and chronic myeloid leukemia
(Greiner L et al. Int J Cancer, August 2020)
– open access publication
Effect of age and comorbidities on the decline of glomerular filtration rate in chronic myeloid leukemia patients discontinuing tyrosine kinase inhibitors
(Lucijanic M & Krecak I. Int J Hematol, August 2020)
– open access publication

Mutations in the BCR-ABL1 kinase domain in patients with chronic myeloid leukemia treated with TKIs or at diagnosis
(Liu J et al. Oncol Lett, August 2020)
– open access publication

Use of generic imatinib as first-line treatment in patients with chronic myeloid leukemia (CML): the GIMS (Glivec to Imatinib Switch) study)
(Genelli M et al. Blood Res, August 2020) (epub ahead of print)
– open access publication
Mutations in the BCR-ABL1 kinase domain in patients with chronic myeloid leukemia treated with TKIs or at diagnosis
(Liu J et al. Oncol Lett, August 2020)
– open access publication
  Lipid nanoparticle-mediated siRNA delivery for safe targeting of human CML in vivo
(Jyotsana N et al. Ann Hematol, August 2020)
– open access publication
July 2020
A British Society for Haematology Guideline on the diagnosis and management of chronic myeloid leukemia
(Smith G et al. Br J Haematol, July 2020) (epub ahead of print)
– open access publication
PVR and ICAM-1 on blast crisis CML stem and progenitor cells with TKI resistance confer susceptibility to NK cells
(Kim N et al. Cancers (Basel), July 2020

Is cancer latency an outdated concept? Lessons from chronic myeloid leukemia
(Abecasis M et al. Leukemia, July 2020)
– open access publication

Tyrosine kinase inhibitors induce alternative spliced BCR-ABL (Ins35bp) variant via inhibition of RNA polymerase II on genomic BCR-ABL
(Yuda J et al. Cancer Sci, July 2020)
– open access publication
Current treatment options for chronic myeloid leukemia patients failing second-generation tyrosine kinase inhibitors
(García-Gutiérrez V & Hernández-Boluda JCC. J Clin Med, July 2020)
– open access publication
Integrin-linked kinase mediates therapeutic resistance of quiescent CML stem cells to tyrosine kinase inhibitors
(Rothe K et al. Cell Stem Cells, July 2020)
(epub ahead of print)  
Surrogate markers for treatment-free remission in patients with chronic myeloid leukemia
(Ureshino H et al. Clin Lymphoma Myeloma Leuk, July 2020) (epub ahead of print)
- open access publication
Therapeutic inhibition of FcγRIIb signaling targets leukemia stem cells in chronic myeloid leukemia
(Parting O et al. Leukemia, July 2020)
(epub ahead of print)
- open access publication 
Comparison of BCR-ABL1 quantification in pheripheral blood and bone marrow using an International scale-standardized assay for assessment of deep molecular response in chronic myeloid leukemia
(Greiner G et al. Clin Chem Lab Med, July 2020) – open access publication
Acriflavine targets oncogenic STAT5 signaling in myeloid leukemia cells
(Hallal R et al. J Cell Mol Med, July 2020)
(epub ahead of print)
– open access publication 
Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia
(Abaza Y et al. Am J Hematol, July 2020) (epub ahead of print)
Targeting SKP2/BCR-ABL pathway with Diosmetin suppresses chronic myeloid leukemia proliferation
(Liu Y et al. Eur J Pharmacol, July 2020)
(epub ahead of print)
Fatigue in chronic myeloid leukemia patients on tyrosine kinase inhibitor therapy: predictors and the relationship with physical activity
(Janssen L et al. Haematologica, July 2020)
 
Late molecular recurrences in patients with chronic myeloid leukemia experiencing treatment-free remission
(Rousselot P et al. Blood Adv, July 2020)
– open access publication
 
Another set of guidelines for chronic myeloid leukaemia
(Clark RE. Br J Haematol, July 2020)
(epub ahead of print)
 
Evidence of BCR-ABL1-positive progenitor spread in blood during molecular recurrence after TKI discontinuation in chronic myeloid leukemia (CML)
(Turhan AG et al. Leuk Lymphoma, July 2020)
 
Platelet function in patients with chronic myeloid leukemia treated with asciminib
(Nesr G et al. Leuk Lymphoma, July 2020)
(epub ahead of print)
 
Timing for allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients
(Hu B et al. Leuk Lymphoma, July 2020)
(epub ahead of print)
 
June 2020
The EUTOS long-term survival (ELTS) score is superior to the Sokol score for predicting survival in chronic myeloid leukemia
(Pfirrmann M et al. Leukemia, June 2020) (epub ahead of print)
- open access publication
An integrative model of pathway convergence in genetically heterogenous blast crisis chronic myeloid leukemia
(Ko TK et al. Blood, June 2020)
(epub ahead of print)  
First-line imatinib vs second- and third-generation TKI’s for chronic phase CML:
a systematic review and data analysis
(Vener C et al. Blood Adv, June 2020)
– open access publication
Epigenetic and functional changes imposed by NUP98-HOXA9 in a genetically engineered model of chronic myeloid leukemia progression
(Sloma I et al. Haematologica, June 2020)
(epub ahead of print)
- open access publication 
Influence of major BCR-ABL1 transcript subtype on outcomes in patients with chronic myeloid leukemia in chronic phase treated frontline with nilotinib
(Gentham A et al. Oncotarget, June 2020) – open access publication
The HDAC6 inhibitor 7b induces BCR-ABL ubiquitation and downregulation and synergizes with imatinib to trigger apoptosis in chronic myeloid leukemia
(Losson H et al. Pharmacol Res, June 2020)
(epub ahead of print
Current strategies and future directions to achieve deep molecular response and treatment-free remission in chronic myeloid leukemia
(Annunziata M et al. Front Oncol, June 2020)
– open access publication
Micro RNA-153-3p enhances the sensitivity of chronic myeloid leukemia cells to imatinib by inhibiting B-cell lymphoma-2 mediated autophagy
(Li YL et al. Hum Cell, July 2020)
Chronic myeloid leukemia prognosis and therapy: Criticisms and perspectives
(Russo D et al. J Clin Med, June 2020)
– open access publication
Inhibition of USP1, a new partner of BCR-ABL, results in decrease of BCR-ABL level in K562 cells
(Antonenko SV et al. Exp Oncol June 2020)
Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study
(Hochhaus A et al. Leukemia, June 2020)
(epub ahead of print)
- open access publication
Blastic transformation of BCR-ABL1 positive chronic myeloid leukemia through acquisition of CBFB-MYH11 and mutant KIT
(Shoumariyeh K et al. B J Haematol, June 2020)
(epub ahead of print)
-open access publication
How many chronic myeloid leukemia patients who started a frontline second-generation tyrosine kinase inhibitor have to switch to a second-line treatment?
A retrospective analysis from the monitoring registries of the Italian Medicines Agency (AIFA)
(Breccia M et al. Cancer Med, June 2020)
– open access publication
 
Clinical utility of genomic DNA Q-PCR for the monitoring of a patient with atypical e19a2 BCR-ABL1 transcripts in chronic myeloid leukemia
(Pagani IS et al. Leuk Lymphoma, June 2020)
(epub ahead of print)
 
The clinical impact of time to response in de Novo accelerated-phase chronic myeloid leukemia
(Ohanian M et al. Am J Hematol, June 2020)
(epub ahead of print)
 
May 2020
Expert opinion-management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors
(Hochhaus A et al. Leukemia, May 2020) (epub ahead of print)
- open access publication
Chronic myeloid leukemia with insertion-derived BCR-ABL1 fusion: redefining complex chromosomal abnormalities by correlation of FISH and karyotype predicts prognosis
(Tang Z et al. Mod Pathol, May 2020)
(epub ahead of print)  

High-risk additional chromosomal abnormalities at low blast counts herald death by CML
(Hehlmann R et al. Leukemia, May 2020) (epub ahead of print)
– open access publication

Monitoring of minimal residual disease (MRD) in chronic myeloid leukemia: Recent advances
(Cumbo C et al. Cancer Manag Res, May 2020)
– open access publication 
Analysis of chronic myeloid leukemia during deep molecular response by genomic PCR: a traffic light stratification model with impact on treatment-free remission
(Machova Polakova K et al. Leukemia, May 2020) (epub ahead of print)
Novel multiplex droplet digital PCR assays to monitor minimal residual disease in chronic myeloid leukemia patients showing atypical BCR-ABL1 transcripts
(Petiti J et al. J Clin Med, May 2020)
– open access publication  
Delayed resistance to imatinib after 16 years of therapy in a patient with chronic myeloid leukemia
(Kaur U et al. Br J Haematol, May 2020)
(epub ahead of print)
- open access publication
Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells
(Lernoux M et al. Clin Epigenetics, May 2020)
– open access publication
Prolonged treatment-free remission in chronic myeloid leukemia patients with previous BCR-ABL1 kinase domain mutations
(Claudiadini S et al. Haematologica, May 2020)
(epub ahead of print)
- open access publication
ERBB2/HER2 mutations are transforming and therapeutically targetable in leukemia
(Joshi SK. Leukemia, May 2020) (epub ahead of print)
- open access publication
Risk of molecular recurrence after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia patients: a systematic review of literature with a meta-analysis of studies over the last ten years
(Dulucq S et al. Br J Haematol, May 2020)
– open access publication
Coexistance of breakpoint cluster region-Abelson1 rearrangement and Janus kinase 2 V617F mutation in CML: A case report
(Shi XB et al. World J Clin Cases, May 2020)
– open access publication
Treatment-free remission in patients with chronic myeloid leukemia
(Ross DM and Hughes TP. Nat Rev Clin Oncol, May 2020) (epub ahead of print)
Phosphorylation of BECLIN-1 by BCR-ABL suppresses autophagy in chronic myeloid leukemia
(Yu C et al. Haematologica, May 2020)
– open access publication
Cardiovascular mortality among chronic myeloid leukemia patients in the pre-tyrosine kinase inhibitor (TKI) and TKI eras: a surveillance, epidemiology and end results (SEER) analysis
(Wang Q et al. Leuk Lymphoma, May 2020)
Recruiting TP53 to target chronic myeloid leukemia stem cells
Grant S. Haematologica, May 2020 – open access publication
http://www.haematologica.org/content/105/5/1172
  ABL genomic editing sufficiently abolished oncogenesis of human chronic myeloid leukemia cells in vitro and in vivo
(Chen SH et al. Cancers (Basel), May 2020)
– open access publication
  Clonal evolution of AML1-ETO coexisting with BCR-ABL and additional chromosome abnormalities in a blastic transformation of chronic myeloid leukemia
(Ma CC et al. J Int Med Res, May 2020)
– open access publication
  High-risk additional chromosomal abnormalities at low blast counts herald death by CML
(Hehlmann R et al. Leukemia, May 2020)
(epub ahead of print) - open access publication
  Novel multiplex droplet digital PCR assays to monitor minimal residual disease in chronic myeloid leukemia patients showing atypical BCR-ABL1 transcripts
(Petiti J et al. J Clin Med, May 2020) – open access publication
  Specific, targetable interactions with the microenvironment influence imatinib-resistant chronic myeloid leukemia
(Kumar R et al. Leukemia, May 2020)
(epub ahead of print) - open access publication

Down-regulating NQO1 promotes cellular proliferation in K562 cells via elevating DNA synthesis
(Xiao FY et al. Life Sci, May 2020)
– open access publication 
  Clonal evolution of AML1-ETO coexisting with BCR-ABL and additional chromosome abnormalities in a blastic transformation of chronic myeloid leukemia
(MA CC et al. J Int Med Res, May 2020)
– open access publication 
April 2020
Response and resistance to BCR-ABL1-targeted therapies
(Braun TP et al. Cancer Cell, April 2020)
Nobiletin promotes megakaryocytic differentiation through the MAPK/ERK-dependent EGR1 expression and exerts anti-leukemic effects in human chronic myeloid leukemia (CML) K562 cells
(Yen JH et al. Cells, April 2020)
– open access publication 
Successful treatment-free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased killer cells
(Irani YD et al. Br J Haemaol, April 2020)
(epub ahead of print)
– open access publication
Overexpression of IFIT2 inhibits the proliferation of chronic myeloid leukemia cells by regulating the BCR-ABL/AKT/mTOR pathway
(Zhang Z et al. Int J Mol Med, April 2020
Relationship between molecular response and quality of life with bosutinib or imatinib for chronic myeloid leukemia
(Brümmendorf TH et al. Ann Hematol, April 2020)
(epub ahead of print)
- open access publication
Genotype-phenotype correlation of unusual BCR-ABL1 transcripts in Philadelphia chromosome-positive leukemia
(Gong Z et al. Br J Haematol, April 2020)
(epub ahead of print)
- open access publication
Venetoclax and BCR-ABL tyrosine kinase inhibitor combinations: outcome in patients with Philadelphia chromosome-positive advanced myeloid leukemias
(Maiti A et al. Acta Haematol, April 2020)
(epub ahead of print)
The miR-185/PAK6 axis predicts therapy response and regulates survival of drug-resistant leukemia
stem cells in CML (Lin H et al. Blood, April 2020)
(epub ahead of print
Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study
(Cortes JE et al. Leukemia, April 2020)
(epub ahead of print)
– open access publication
Response and resistance to BCR-ABL-1 targeted therapies
(Braun TP et al. Cancer Cell, April 2020
Metabolic analysis of patients with chronic myeloid leukemia and cardiovascular adverse events after treatment with tyrosine kinase inhibitors
(Caocci et al. J Clin Med, April 2020)
– open access publication
GZD824 as a FLT3, FGFR1 and PDGFR-alpha inhibitor against leukemia in vitro and in vivo
(Wang Y et al. Transl Oncol, April 2020)
(epub ahead of print)
- open access publication 
Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring
(Jabbour E and Kantarjian H. Am J Hematol, April 2020) (epub ahead of print)
Basic knowledge on BCR-ABL1-positive extracellular vesicles
(Jurj A et al. Biomark Med, April 2020)
(epub ahead of print
Optimal treatment strategy with nilotinib for patients with newly diagnosed chronic-phase chronic myeloid leukemia based on early achievement of deep molecular response (MR4.5): The phase 2, multicenter N-Road study
(Nishiwaki K et al. Cancer Med, April 2020)
(epub ahead of print)
- open access publication 
Separase activity distribution can be a marker of major molecular response and proliferation of CD34+ cells in TKI-treated chronic myeloid leukemia patients
(Spiess D et al. Ann Hematol, April 2020)
(epub ahead of print)
– open access publication
The differentiated diagnosis of basophilia in patients undergoing BCR-ABL testing
(Smith CJ et al. Am J Hematol, April 2020)
(epub ahead of print)
- open access publication 
A novel chimeric antigen receptor redirecting T-cell specificity towards CCD26+ cancer cells
(Zhou S et al. Leukemia, April 2020) (epub ahead of print)
Phase 2 study of bosutinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia
(Hino M et al. Int J Hematol, April 2020)
(epub ahead of print
TKIs induce alternative spliced BCR-ABLIns35bp variant via inhibition of RNA polymerase II on genomic BCR-ABL
(Yuda J et al. Cancer Sci, April 2020) (epub ahead of print)
- open access publication
How many chronic myeloid leukemia patients who started a frontline second-generation tyrosine kinase inhibitor have to switch to a second-line treatment?
A retrospective analysis frontline monitoring registries of the Italian Medicines Agency (AIFA)
(Breccia M et al. Cancer Med, April 2020)
(epub ahead of print)
- open access publication
Induction of CML-specific immune response through cross-presentation triggered by CTP-mediated BCR-ABL-derived peptides
(Yang H et al. Cancer Lett, April 2020) (epub ahead of print)
  Synthesis and characterization of Telmisartan-derived cell death modulators to circumvent imatinib resistance in chronic myeloid leukemia
(Gust R et al. ChemMedChem, April 2020) (epub ahead of print)
- open access publication
  Role of DNA damage response in suppressing malignant progression of chronic myeloid leukemia and Polycythemia Vera: Impact of different oncogenes
(Stetka J et al. Cancers (Basel), April 2020)
– open access publication
March 2020
TARGET: a survey of real-world management of chronic myeloid leukemia across 33 countries
(Turkina A et al. Br J Haematol, March 2020)
(epub ahead of publication)
Correction of Bcl-x splicing improves responses to imatinib in chronic myeloid leukaemia cells and mouse model
(Zhang J et al. Br J Haematol, March 2020)
(epub ahead of print)

Risk stratification of chronic myeloid leukemia according to different prognostic scores
(Aijaz J et al. Cureus, March 2020)
– open access publication

An integrative model of pathway convergence in genetically heterogenous blast crisis chronic myeloid leukemia
(Ko TH et al. Blood, March 2020) (epub ahead of print
Patient-initiated discontinuation of tyrosine kinase inhibitor for chronic myeloid leukemia
(Langabeer SE et al. Case Rep Hematol, March 2020)
– open access publication
Pseudolaric acid B induces mitotic arrest and apoptosis in both imatinib-sensitive and –resistant chronic myeloid leukemia cells
(Jiang L et al. Eur J Pharmacol, March 2020)
(epub ahead of print)
open access publication  
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
(Hochhaus A et al. Leukemia, March 2020)
(epub ahead of print)open access publication
Deubiquitylase USP25 prevents degradation of BCR-ABL protein and ensures proliferation of Ph-positive leukemia cells
(Shibata N et al. Oncogene, March 2020)
(epub ahead of print
Pharmacokinetics of dasatinib in hemodialysis patient with chronic myeloid leukemia and chronic kidney disease
(Mori J et al. Int J Hematol, March 2019)
(epub ahead of print)

SIRT7: an influence factor in healthy aging and the development of age-dependet myeloid stem cell disorders
(Kaiser A et al. Leukemia, March 2020)
(epub ahead of print)

 
Treatment outcomes of chronic-phase chronic myeloid leukemia with resistance and/or intolerance to a 1st-line tyrosine kinase inhibitor in Japan: the results of the new TARGET study 2nd line
(Sakurai M et al. Int J Hematol, March 2020)
(epub ahead of print)
Ponatinib induces vascular toxicity through the Notch-1 signaling pathway
(Madonna R et al. J Clin Med, March 2020)
open access publication
The multi-tyrosine kinase inhibitor ponatinib for chronic myeloid leukemia: Real-world data
(Luciano L et al. Eur J Haematol, March 2020)
(epub ahead of print)- open access publication
Involvement of MCL-1, c-myc, and cyclin D2 protein degradation in ponatinib-induced cytotoxicity against T315l(+) Ph+leukemia cells
(Inoue C et al. Biochem Biophys Res Commun, March 2020) (epub ahead of print)

Novel therapeutic approaches in chronic myeloid leukemia
(Özgür Y et al. Leuk, February 2020)
(epub ahead of print)

 

Experience of living with chronic myeloid leukemia and adhering to tyrosine kinase inhibitors: A thematic synthesis of qualitative studies
(Hewison A et al. Eur J Oncol Nurs, February 2020)
open access publication

 

 

BCR-ABL1 transcript decline ratio combined BCR-ABL1IS as a precise predictor for imatinib response and outcome in the patients with chronic myeloid leukemia
(Cai Z et al. J Cancer, February 2020)
open access publication

 
Is it beneficial to use hydroxychloroquine and imatinib combination in order to achieve deeper molecular responses in patients with chronic myeloid leukemia
(Eskazan AE. Leukemia, March 2020)
(epub ahead of print)

 

 
Does patient sex play a role in treatment-free remission in chronic myeoid leukemia?
(Ureshino H et al. Int J Hematol, March 2020)
(epub ahead of print)
 
Significance of lymphocyte count, monocyte count, and lymphocyte-to-monocyte ratio in predicting molecular response in patients with chronic myeloid leukemia: A single center experience
(Pepedil-Tanrikulu F et al. Clin Lab, March 2020)
 
Influence of proton pump inhibitors and H2-receptor antagonists on the efficacy and safety of dasatinib in chronic myeloid leukemia patients
(Koutake Y et al. Int J Hematol, March 2020)
(epub ahead of print)
 
February 2020
Side-effect profile and outcomes of ponatinib in the treatment of chronic myeloid leukemia
(Chan O et al. Blood Adv, February 2020)
– open access publication 
Phosphorylation-dependent differences in CXCR4-LASP-AKT1 interaction between breast cancer and chronic myeloid leukemia
(Butt E et al. Cells, February 2020)
open access publication
Prospects of achieving treatment-free remission in chronic myeloid leukemia)
(Saglio G et al. Br J Haematol, February 2020)
(epub ahead of print)
- open access publication
Aberrant RAG-mediated recombination contributes in lymphoid blast crisis of chronic myeloid leukemia
(Thomson DW et al. Leukemia, February 2020)
(epub ahead of print
Risk of molecular recurrence after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia patients: a systematic review of literature with a meta-analysis of studies over the past ten years
(Dulucq S et al. Br J Hematol, February 2020)
(epub ahead of print)
Model-based inference and classification of immunological control mechanism from TKI cessation and dose reduction in CML patients
(Hähnel T et al. Cancer Res, February 2020)
(epub ahead of print
Cardiovascular mortality among chronic myeloid leukemia patients in the pre-tyrosine kinase inhibitor (TKI) and TKI eras: a surveillance, epidemiology and end results analysis
(Wang Q et al. Leuk Lymphoma, January 2020)
(epub ahead of print)
Comparison of BCR-ABL 1 quantification in peripheral blood and bone marrow using an international scale-standardized assay for assessment of deep molecular response in chronic myeloid leukemia
(Greiner G et al. Clin Chem Lab Med, February 2020)
(epub ahead of print
Mechanisms of cardiovascular toxicity of BCR-ABL 1 tyrosine kinase inhibitors in chronic myelogenous leukemia
(Gustafson D et al. Curr Hematol Rep, February 2020)
(epub ahead of print)
Investigating the role of the innate immune response in relapse or blast crisis in chronic myeloid leukemia
(Huang W et al. Leukemia, February 2020)
(epub ahead of print)
- open access publication
A single center evaluation of cost savings related to treatment-free remission in chronic myeloid leukemia patients: the prerequisites of a pharmaco-economy larger study
(Etienne G et al. Br J Haematol, February 2020)
(epub ahead of print
SRSF1 mediates cytokine induced impaired imatinib sensitivity in chronic myeloid leukemia
(Sinnakannu JK et al. Leukemia, February 2020)
(epub ahead of print)
Novel illumine-based next generation sequencing approach with one-round amplification provides early and reliable detection of BCR-ABL1 kinase domain mutations in chronic myeloid leukemia
(Romzova M et al. Br J Hematol, February 2020)
(epub ahead of print
Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemia
(Adnan Awad S et al. Blood Adv, February 2020)
– open access publication
What’s NEXT for CML-NGS mutation screening?
(Shanmunagathan N et al. Blood, February 2020)

The landscape of BCR-ABL mutations in patients with Philadelphia chromosome-positive leukaemias in the era of second-generation tyrosine kinase inhibitors
(Chien SH et al. Hematol Oncol, February 2020)
(epub ahead of print)

 
  DNA damage and DNA damage response in chronic myeloid leukemia
(Popp HD et al. Int J Mol Sci, February 2020)
– open access publication
 

Nanomaterials as magic bullets in the treatment of leukemia
(Houshmand M et al. Nanomaterials (Basel), February 2020)
open access publication

January 2020
Long-term results of a phase 2 trial of nilotinib 400 mg twice daily in newly diagnosed patients with chronic-phase chronic myeloid leukemia
(Masarova L et al. Cancer, January 2020) (epub ahead of print)
The vascular bone marrow niche influences outcome in chronic myeloid leukemia via the E-selectin SCT/TAL-1 – CD44 axis
(Godavarthy PS et al. Haematologica, January 2020)
– open access publication 
Long-term results of frontline dasatinib in chronic myeloid leukemia
(Maiti A et al. Cancer, January 2020)
(epub ahead of print)
How does the novel T315L mutation of breakpoint cluster region-abelson (BCR-ABL) kinase confer resistance to ponatinib: a comparative molecular dynamics simulation study
(Zhang H et al. J Biomol Strat Dyn January 2020
Molecular dynamics during reduction of TKI dose reliably identify molecular recurrence after treatment cessation of CML
(Gottschalk A et al. Blood, January 2020)
(epub ahead of print)  

Plasma proteomics of biomarkers for inflammation or cancer cannot predict relapse in chronic myeloid leukemia patients stopping tyrosine kinase inhibitor therapy
(Söderlund S et al. Leuk Res, January 2020)
(epub ahead of print)


A randomized phase II trial of hydroxychloroquine and imatinib alone for patients with chronic myeloid leukemia in major cytogenetic response with residual disease
(Horne GA et al. Leukemia, January 2020)
(epub ahead of print) 

The leukemia stem cell: similarities, differences and clinical prospects in CML and AML
(Vetrie D et al. Nat Rev Cancer, January 2020)
(epub ahead of print)
Treatment patterns and deep molecular response in chronic-phase – chronic myeloid leukemia patients treated with second-line nilotinib or dasatinib: a multi-country retrospective chart review study
(Cortes J et al. Leuk Lymphoma, January 2020
CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy
(Kinstrie R et al. Leukemia, January 2020)
(epub ahead of print)
What are the considerations for tyrosine kinase inhibitor discontinuation in chronic phase chronic myeloid leukemia?
(Harrington P et al. Expert Rev Hematol, January 2020)
(epub ahead of print)
Knock-out of LASP1 in CXCR4 expressing CML cells promotes cell persistence, proliferation and TKI resistance
(Herrmann AD et al. J Cell Mol Med, January 2020)
(epub ahead of print)
– open access publication

Successful planned pregnancy through vitrified-warmed embryo transfer in a women with chronic myeloid leukemia: Case report and literature review
(Furukawa Y et al. Mediterr J Hematol Infect Dis, January 2020) – open access publication

Defining the niche interactions to target chronic myeloid leukemia stem cells
(Mitchell R et al. Haematologica, January 2020)
– open access publication
Treatment-free remission after first-line dasatinib treatment in patients with chronic myeloid leukemia in the chronic phase: the D-NewS study of the Kanto CL Study Group
(Yamaguchi H et al. Int J Hematol, January 2020)
(epub ahead of print)
The vascular bone marrow niche influences outcome in chronic myeloid leukemia via the E-selectin – SCL/TAL1 – CD44 axis
(Godavarthy PS et al. Haematologica, January 2020)
– open access publication 
  Human telomerase reverse transcriptase depletion potentiates the growth-inhibitory activity of imatinib in chronic myeloid leukemia stem cells
(Grandjenette C et al. Cancer Lett, January 2020)